Sun Pharmaceutical Industries' subsidiary, Sun Pharma Laboratories Ltd, has approved a Rs 3,000 crore investment for a new greenfield formulations manufacturing facility in Madhya Pradesh. This significant expansion by the Mumbai-based drug major aims to bolster its production capabilities. The announcement comes as Sun Pharma's shares saw a slight increase on Wednesday.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F76BokX
via IFTTT
-
Acquista ********, Ossicodone, Ketamina, Ozempic (WhatsApp: +31616337954) I nostri prodotti hanno una purezza del 98-99%. E-mail di cont...
-
So I’m currently on a lean bulk on 2900 a day. And I wake up 6 am I have oats and protein powder or fruit then go gym around 9 am Then at ...
-
Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales ...
Search This Blog
Powered by Blogger.
Blog Archive
-
▼
2025
(778)
-
▼
December
(13)
- Abbott asks stockists to buy only from authorised ...
- Lupin gets USFDA nod for multiple sclerosis drug
- AI and technology tackling India’s growing stroke ...
- GSK India plans big 'reinvention', MD Bhushan Aksh...
- NABL accreditation sets the stage for Lords Mark M...
- Details of failed studies cast pall on Novo Nordis...
- Sun Pharma unit to invest Rs 3,000 cr on new plant...
- India weight-loss market reset? In setback for Nov...
- Novo Nordisk India partners with Healthify to laun...
- HC lets Dr Reddy's Laboratories export Semaglutide...
- Jubilant Pharmova names Daniel J O'Connor as CEO o...
- Cough syrup row puts regulators on overdrive to te...
- Wockhardt gets NDA status for novel antibiotic Zay...
-
▼
December
(13)
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment